Positive phase 2 results reported for novel combination therapy for Parkinson's disease
CuraSen Therapeutics Inc. announced positive data from its randomized, double-blind crossover phase 2 study of CST-103/CST-107, which demonstrated improvements in cognition and mood in those with Parkinson’s disease.According to a CuraSen release, the study — which took place at locations in Australia, Belgium, New Zealand and the U.K. — evaluated the novel combination of